Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,367 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dextrose Control Clear all
Completed Not applicable Interventional

Time Limited Eating in Adolescents With Type 2 Diabetes (KT2D)

NCT04536480
View directory record Official record
Conditions
Pediatric Obesity, Type 2 Diabetes, Time Restricted Eating
Interventions
Time Limited Eating, Components Common to All Study Arms., Control, Continuous Glucose Monitor
Behavioral · Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
12 Years to 21 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Results available

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

NCT01195662
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo matching Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 89 Years
Enrollment
2,245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 117 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 29, 2026, 2:25 AM EDT
Not listed Not applicable Interventional

Towards Understanding the Relationship Between Meals and Blood Biomarkers

NCT05295706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Counterfactual Intervention
Behavioral
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Markers of Atherosclerosis in Overweight, Postmenopausal Women Following Daily Watermelon Consumption

NCT04015544
View directory record Official record
Conditions
Postmenopausal, Overweight and Obesity
Interventions
Watermelon
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Boone, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 29, 2026, 2:25 AM EDT
Withdrawn Not applicable Interventional

Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT

NCT04227626
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions
GlucoSTAT
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 29, 2026, 2:25 AM EDT
Active, not recruiting Phase 3 Interventional

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

NCT04919226
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
Drug · Other
Lead sponsor
ITM Solucin GmbH
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Palo Alto, California • Aurora, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 29, 2026, 2:25 AM EDT
Terminated Not applicable Interventional Results available

Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin

NCT03455985
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Patient Discharge, Blood Glucose, Low, Blood Glucose, High
Interventions
Discharge Order Set (DOS), Enhanced Standard Care (ESC)
Other
Lead sponsor
Ohio State University
Other
Eligibility
25 Years to 75 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 29, 2026, 2:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

C-reactive Protein and Endothelial Dysfunction in Women With Glucose Intolerance

NCT00589355
View directory record Official record
Conditions
Glucose Intolerance
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 1Phase 2 Interventional

Joint Injections for Osteoarthritic Knee Pain

NCT00085722
View directory record Official record
Conditions
Osteoarthritis
Interventions
Dextrose Prolotherapy, Saline Prolotherapy, At-home physical therapy exercise group
Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
40 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

NCT04039503
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Fresno, California • New Port Richey, Florida • Nashua, New Hampshire + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 29, 2026, 2:25 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

NCT01851694
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
GLP-1, GIP
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 29, 2026, 2:25 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Postprandial Response to Fruit Juice

NCT07103083
View directory record Official record
Conditions
Blood Glucose, Blood Insulin
Interventions
Beverage 1, Beverage 2, Beverage 3, Beverage 4, Beverage 5, Beverage 6
Dietary Supplement
Lead sponsor
Ocean Spray Cranberries, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 2Phase 3 Interventional

Dextrose Gel Does Not Prevent Neonatal Hypoglycemia

NCT02523222
View directory record Official record
Conditions
Hypoglycemia, Infant, Small for Gestational Age, Premature Birth of Newborn, Fetal Macrosomia, Intrauterine Growth Restriction, Complication of Prematurity, Neonatal Hypoglycemia
Interventions
40% Dextrose gel
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
0 Hours to 1 Hour
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 3 Interventional

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

NCT03847428
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Bevacizumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
34
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Not applicable Interventional Results available

Effect of Gain on Closed-Loop Insulin

NCT02065895
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
HIGH error, NO error, LOW error
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 4 Interventional Results available

Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation

NCT00779701
View directory record Official record
Conditions
Hyperglycemia
Interventions
Insulin
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 4 Interventional

CGM - Reimagine Primary Care

NCT04413578
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dexcom G6, Contour NextOne
Device
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Holladay, Utah • Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Not applicable Interventional

Resilience-Based Diabetes Self-Management Education (RB-DSME) for African Americans

NCT04282395
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Resilience-Based Diabetes Self-Management Education, Standard Diabetes Self-Management Education
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 29, 2026, 2:25 AM EDT
Active, not recruiting Not applicable Interventional

AIDANET Pediatrics

NCT07020936
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Normal Glycemia Goal, Tight Glycemia Goal
Device
Lead sponsor
Mark D. DeBoer, MD, MSc., MCR
Other
Eligibility
6 Years to 13 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes

NCT01475734
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 29, 2026, 2:25 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children

NCT01072370
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Cord Blood Infusion, Intravenous Sham
Biological
Lead sponsor
Augusta University
Other
Eligibility
1 Year to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 29, 2026, 2:25 AM EDT
Active, not recruiting Not applicable Interventional Results available

Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Pediatric T1D - 4T Study

NCT04336969
View directory record Official record
Conditions
Type1diabetes
Interventions
4T Education and Care
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 21 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Aspartame on Appetite, Body Composition and Oral Glucose Tolerance

NCT02999321
View directory record Official record
Conditions
Oral Glucose Tolerance
Interventions
aspartame, water
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 60 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 29, 2026, 2:25 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Comparison of Neuromuscular Recruitment in Trained and Untrained Adults

NCT06820658
View directory record Official record
Conditions
Healthy, Insulin Resistance
Interventions
Neuromuscular Test, DEXA, Mixed Meal Tolerance Test, Strength Test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 29, 2026, 2:25 AM EDT